Inducible bronchus-associated lymphoid tissue (iBALT), the tertiary immune organ in the lungs, has been implicated in various pulmonary diseases. The formation and roles of iBALTs in neutrophilic allergic asthma, however, remain largely unexplored. In our study, iBALTs were located near bronchi and vessels in a neutrophilic asthma murine model induced by house dust mite (HDM) extract and lipopolysaccharide (LPS). Repeated sensitization promoted the formation of iBALTs, which disappeared 2 weeks after the last HDM challenge. We disrupted the function of B-cell chemokines (C-X-C motif chemokine ligand 13, CXCL13). The CXCL13 neutralizing antibody prevented the formation of iBALTs but failed to relieve airway inflammation. Bulk RNA-seq revealed elevated MMP-12 in pulmonary B lymphocytes, a major population in iBALTs. MMP408, a specific MMP-12 inhibitor, reduced iBALT formation. Moreover, a modified AAV-6 (adeno-associated virus-6) targeting MMP-12 in B lymphocytes blocked iBALTs and ameliorated neutrophilic airway inflammation. These results indicate that MMP-12 produced by B lymphocytes promotes the aggregation of B lymphocytes, promotes the formation of iBALTs, and further exacerbates inflammation in neutrophilic allergic asthma.